CLS Lipid Panel Interpretation 3

Question 1

A 52-year-old woman has LDL-C 135 mg/dL, HDL-C 42 mg/dL, TG 155 mg/dL, and TC 208 mg/dL. Her 10-year ASCVD risk is 9.8%. According to ACC/AHA guidelines, what is the most appropriate next step?

Accepted Answer

Discuss risk-enhancing factors and consider moderate-intensity statin

Answer

For intermediate-risk patients (7.5–20% 10-year ASCVD risk), ACC/AHA guidelines recommend a risk discussion incorporating risk-enhancing factors before initiating moderate-intensity statin therapy.

Question 2

Which of the following best defines the LDL-C treatment goal for a patient with established ASCVD and a recent ACS event (very high-risk)?

Accepted Answer

<55 mg/dL

Answer

For very high-risk ASCVD patients (including those with recent ACS), 2022 ACC/AHA guidelines recommend an LDL-C goal of <55 mg/dL with a ≥50% reduction from baseline.

Question 3

A fasting lipid panel shows TC 240 mg/dL, HDL-C 60 mg/dL, TG 100 mg/dL, LDL-C 160 mg/dL. Calculated non-HDL is 180 mg/dL. How does this panel affect ASCVD risk interpretation?

Accepted Answer

High HDL-C partially offsets the elevated LDL-C and should be factored into risk assessment

Answer

HDL-C ≥60 mg/dL is considered a negative risk factor that partially offsets cardiovascular risk and should be incorporated into overall ASCVD risk assessment alongside other lipid values.

Question 4

A patient on maximally tolerated statin plus ezetimibe has LDL-C 78 mg/dL with very high-risk ASCVD. Which interpretation is most accurate?

Accepted Answer

LDL-C remains above the <55 mg/dL very-high-risk target; PCSK9 inhibitor addition is appropriate

Answer

For very high-risk ASCVD patients with LDL-C above 55 mg/dL despite maximally tolerated statin plus ezetimibe, adding a PCSK9 inhibitor is guideline-supported to achieve the LDL-C goal.

Question 5

Which lipid panel component most directly reflects the number of atherogenic lipoprotein particles when LDL-C and triglycerides are discordant?

Accepted Answer

Apolipoprotein B

Answer

Apolipoprotein B (apoB) measures the total number of atherogenic lipoprotein particles (each containing one apoB molecule) and provides more accurate risk assessment than LDL-C when there is LDL-TG discordance.

(CLS) Clinical Lipid Specialist Certification Practice Test

(CLS) Clinical Lipid Specialist Certification Practice Test

CLS Lipid Panel Interpretation 3